Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celldex commences rindopepimut combination trial
The trial ‘ReACT Study’ will run in parallel with Celldex’s Phase 3 trial (ACT IV) evaluating rindopepimut in patients with newly diagnosed EGFRvIII-expressing glioblastoma (GB). Rindopepimut is an
The trial ‘ReACT Study’ will run in parallel with Celldex’s Phase 3 trial (ACT IV) evaluating rindopepimut in patients with newly diagnosed EGFRvIII-expressing glioblastoma (GB). Rindopepimut is an
As per the agreement, Ironwood will develop and commercialize Bionomics’ investigational anti-anxiety compound BNC210 and other related compounds. Under the collaboration, Bionomics may receive up to $345m in
The company will also adopt Cegedim Relationship Management’s OneKey, the global healthcare professional (HCP) database, and insightful Mobile Intelligence Analytics. Pharmaceutical CRM Solution is believed to deliver Operational
Berinert is a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder. According to the company,
Halaven is a non-taxane, microtubule dynamics inhibitor that is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. Halaven
MacuCLEAR has also entered into a strategic partnership with a Pacific Rim pharmaceutical partner and investor to finance clinical costs, bridging studies and regulatory development for MC-1101 in
Genentech will make use of Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target. Vernalis CEO Ian Garland said the company is happy that Genentech chose
As per the agreement Vifor Pharma is granted an exclusive license for the Isotechnika’s drug, voclosporin, to treat lupus and all proteinuric nephrology indications (the Vifor Pharma License).
The last and third module of the application is backed by the findings from the final phase of clinical testing, which involved the use of the OraQuick Rapid
The monoclonal antibody will be engineered by GBI’s collaborative partner, and then GBI will evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for